Ann: FDA Provides Clear Feedback for ODD Approval, page-320

definitely. we all need to be level headed here although I am struggling to keep calm. cartwheels in my head are happening but for this to generate the $$ we all want to see, the trials need to go well first and foremost. this week will give us an idea of what is possible (or even better, what's likely). Then the 390 need to hunker down and wait and hold out. the board would be instrumental also in their recommendations to SH if it comes to take over. many companies in the past advise SH to accept an offer, others advise to reject. I guess that's mostly on hostile takeovers and I would imagine ours would not be one of those.

licensing deal seems a good course to go for first.

we do not want to undersell this. too many of us have waited 10+years for this.

and most importantly, people with MND need this as do any with the other diseases.

seriously hoping the results this week are outstanding for the sake of the patients. the SH value will follow.

FOMO today on the market I expect.

40c indicative opening